National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, Örebro, Sweden.
Ann N Y Acad Sci. 2011 Aug;1230:E19-28. doi: 10.1111/j.1749-6632.2011.06215.x.
The strict human pathogen Neisseria gonorrhoeae has caused gonorrhea for thousands of years, and currently gonorrhea is the second most prevalent bacterial sexually transmitted infection worldwide. Given the ancient nature of N. gonorrhoeae and its unique obligate relationship with humankind over the millennia, its remarkable ability to adapt to the host immune system and cause repeated infections, and its propensity to develop resistance to all clinically useful antibiotics, the gonococcus is an ideal pathogen on which to study the evolution of bacterial pathogenesis, including antimicrobial resistance, over the long term and within the host during infection. Recently, the first gonococcus displaying high-level resistance to ceftriaxone, identified in Japan, was characterized in detail. Ceftriaxone is the last remaining option for empirical first-line treatment, and N. gonorrhoeae now seems to be evolving into a true "superbug." In the near future, gonorrhea may become untreatable in certain circumstances. Herein, the history of antibiotics used for treatment of gonorrhea, the evolution of resistance emergence in N. gonorrhoeae, the linkage between resistance and biological fitness of N. gonorrhoeae, lessons learned, and future perspectives are reviewed and discussed.
严格的人类病原体淋病奈瑟菌(Neisseria gonorrhoeae)已经导致淋病存在了数千年,目前淋病是全球第二大常见的细菌性性传播感染。鉴于淋病奈瑟菌的古老性质及其与人类数千年来独特的强制性关系,它适应宿主免疫系统并导致反复感染的非凡能力,以及其发展出对所有临床有用抗生素的抗性的倾向,淋球菌是研究细菌发病机制(包括抗菌药物耐药性)的理想病原体,包括在长期内和在感染期间在宿主内的进化。最近,在日本首次鉴定出对头孢曲松具有高水平耐药性的淋球菌,并对其进行了详细描述。头孢曲松是经验性一线治疗的最后选择,而淋病奈瑟菌现在似乎正在演变成一种真正的“超级细菌”。在不久的将来,在某些情况下淋病可能变得无法治疗。在此,本文回顾和讨论了用于治疗淋病的抗生素历史、淋病奈瑟菌耐药性出现的演变、淋病奈瑟菌耐药性与生物学适应性之间的联系、吸取的教训和未来展望。